Cellectis SA, the rational genome engineering company specializing in the production of meganuclease recombination systems and in meganuclease engineering, have announced the delivery of two ...
Dublin, March 22, 2022 (GLOBE NEWSWIRE) -- The "Gene Editing beyond CRISPR Market: Focus on Zinc Finger Nucleases, Transcription Activator-Like Effector Nucleases and Meganucleases Edited Therapies: ...
Mutations in Duchenne muscular dystrophy (DMD) are either inducing a nonsense codon or a frameshift. Meganucleases (MGNs) can be engineered to induce double-strand breaks (DSBs) at specific DNA ...
Cellectis Delivers two Meganucleases Targeting the p53 Gene to its Partners in the NETSENSOR Project
Cellectis SA has announced the delivery of two meganucleases targeting the p53 gene to its partners in the NETSENSOR collaborative research project (part of the European Union's 6th Framework program) ...
Dublin, March 03, 2023 (GLOBE NEWSWIRE) -- The "India Gene Editing Technology Business and Investment Opportunities Databook - Q1 2023 Update" report has been added to ResearchAndMarkets.com's ...
Cellectis Says It Can Cut and Paste DNA Sequences with Its “Molecular Scissors” When a meganuclease enters a cell, it can cut out a mutation, repair the cell, and re-edit the genome for the spelling ...
PARIS and SEATTLE, June 29, 2011 /PRNewswire/ -- Cellectis (Alternext: ALCLS), the French genome engineering specialist, announced today the signing of a collaboration agreement with Pregenen, an ...
BIOCITECH PARK, ROMAINVILLE, France, March 13 /PRNewswire/ -- Cellectis SA (NYSE: ALCLS), a world leader in rational genome engineering, has announced today that it filed a patent infringement lawsuit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results